Cancer Blood Test Uses Biophysics to Surpass Accuracy Norms

OTraces has developed and filed patents on math- and physics-based signal processing and noise suppression methods that, when applied to human biology, boost the accuracy of cancer and other disease blood tests to superior levels, and enable the detection and measurement of cytokine activity in the tumor microenvironment (TME) to achieve real time diagnosis of tumor status and immune response without biopsy. These methods also result in simple and very low cost blood tests that can be embedded in cloud-based software, that is instrument-agnostic and scaleable for high volume screening and LDT applications through potential collaborations with business partners worldwide.

The following video presentation demonstrates how proteomic noise suppression works and outlines its industry potential.


Company/Investor Inquiries:
Keith Lingenfelter; Founder and CEO of OTraces, Inc.
phone: +01-301-529-3824
email: keith.lingenfelter@otraces.com

Contact-Media Inquiries:
Nancy Rose Senich
phone: +01-202-262-6996 cell/txt
email: nancy@rose4results.com